

**PRO-PHARMACEUTICALS' SENIOR EXECUTIVES
TO BE FEATURED ON PBS' "WEALTH & WISDOM"**

Financial Television Program to Air the Exclusive Interview

Newton, MA – July 11, 2008 – PBS' financial television series "Wealth & Wisdom" will feature David Platt, Ph.D., and Theodore Zucconi, Ph.D., CEO and President, respectively, of **Pro-Pharmaceuticals, Inc. (AMEX: PRW)**, a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds for the treatment of cancer and fibrosis, over South Florida's television PBS station WXEL on Friday, July 11th at 7:30 PM EDT.

The interview will be posted to the Company's website, www.pro-pharmaceuticals.com, on Monday, July 14th.

About "Wealth & Wisdom"

The theme for the "Wealth & Wisdom" television series is all about building wealth, preserving wealth, distributing wealth---all with wisdom. The show is hosted by Geoff Garbacz and James DiGeorgia. Geoff and has more than 36 years of experience on Wall Street. James DiGeorgia, the editor of the Gold & Energy Advisor and wunderkind, a self-made millionaire before he turned 21, turning a hobby of coin collecting he began at the age of seven into a multi-million dollar business while still a teenager.

About Pro-Pharmaceuticals, Inc. – Advancing Drugs Through Glycoscience®

Pro-Pharmaceuticals is a clinical stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based, target therapeutic compounds for advanced treatment of cancer, liver, microbial and inflammatory diseases. The Company's initial focus is the development of carbohydrate polymers to treat cancer patients. DAVANAT®, the Company's lead product candidate, is a polysaccharide polymer that is in Phase II trials for colorectal and biliary cancer. The Company's technology is also being used to develop new chemical entities to treat liver and kidney fibrosis. The Company is headquartered in Newton, Mass. Additional information is available at www.pro-pharmaceuticals.com.

FORWARD LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products;

uncertainties associated with pre-clinical and clinical trials of our product candidates. More information about those risks and uncertainties is contained in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals.

Contact:

Pro-Pharmaceuticals, Inc.,
Anthony D. Squeglia: 617.559.0033
squeglia@pro-pharmaceuticals.com

The Investor Relations Group
212-825-3210

Investor Relations

Conrad F. Mir
conrad@investorrelationsgroup.com
or
Christine Berni
christine@investorrelationsgroup.com

Public Relations

Laura Colontrelle
lcolontrelle@investorrelationsgroup.com